K. Máhr

Systemic Treatment of Breast Cancer. 1st Central-Eastern European Professional Consensus Statement on Breast Cancer

Z. Horváth, M. Dank, B. Pikó, 2022, Pathology & Oncology Research.

Capecitabine in Combination with Docetaxel in First Line in HER2-Negative Metastatic Breast Cancer: an Observational Study

E. Hitre, Z. Horváth, J. Erfán, 2017, Pathology & Oncology Research.

Pathologic Complete Response Rates After Neoadjuvant Pertuzumab and Trastuzumab with Chemotherapy in Early Stage HER2-Positive Breast Cancer - Increasing Rates of Breast Conserving Surgery: A Real-World Experience

Z. Horváth, T. Csoszi, B. Budai, 2021, Pathology & Oncology Research.

Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor–Positive Metastatic Breast Cancer

A. Makris, S. Kuemmel, P. Schmid, 2019, JAMA oncology.

Abstract OT1-03-12: MANTA: A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer

A. Makris, S. Kuemmel, P. Schmid, 2016 .

[Systemic treatment of breast cancer: professional guideline].

Z. Horváth, M. Dank, B. Pikó, 2020, Magyar onkologia.